Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.60 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.60 |
| ▸ | TYR | P14679 | 1/20 | 0.50 |
| ▸ | BID | P55957 | 3/20 | 0.49 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.49 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.49 |
| ▸ | BAK1 | Q16611 | 2/20 | 0.49 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 1/20 | 0.49 |
| ▸ | EP300 | Q09472 | 1/20 | 0.49 |
| ▸ | KAT2A | Q92830 | 1/20 | 0.49 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.49 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.49 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.49 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 2/20 | 0.47 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | ELANE | P08246 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL574394 | 0.98 | ALOX5 (0.58) | ALOX5PTGS2TYRBIDMCL1 | |
| SCHEMBL574604 | 0.98 | ALOX5 (0.58) | ALOX5PTGS2TYRBIDMCL1 | |
| SCHEMBL574233 | 0.94 | ALOX5 (0.53) | ALOX5PTGS2TYRBIDMCL1 | |
| Parachlorophenol SCHEMBL8332607 | 0.89 | PTGS2 (0.50) | ALOX5PTGS2TYRBIDMCL1 | |
| SCHEMBL1552241 | 0.86 | HSP90AA1 (0.50) | ALOX5PTGS2EGFRERBB2HSP90AA1 | |
| SCHEMBL2355153 | 0.86 | ALOX5 (0.70) | ALOX5PTGS2TYRBIDMCL1 | |
| SCHEMBL11077986 | 0.86 | HSP90AA1 (0.53) | ALOX5PTGS2EGFRERBB2HSP90AA1 | |
| SCHEMBL20164914 | 0.85 | ALOX5 (0.47) | ALOX5PTGS2TYRBIDMCL1 | |
| SCHEMBL8330970 | 0.84 | ALOX5 (0.46) | ALOX5PTGS2TYRBIDMCL1 | |
| SCHEMBL4959229 | 0.84 | ALOX5 (0.68) | ALOX5PTGS2TYRBIDMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140135297-A1 | AQUEOUS VOLATILE ORGANIC COMPOUND FREE DISINFECTANT AND/OR CLEANING COMPOSITION AND METHOD OF PREPARATION | ISP INVESTMENTS INC. (US) | 2014-05-15 | — | — | US | claimed |
| WO-2012170841-A1 | AN AQUEOUS VOLATILE ORGANIC COMPOUND FREE DISINFECTANT AND/OR CLEANING COMPOSITION AND METHOD OF PREPARATION | ISP INVESTMENTS INC. (US) | 2012-12-13 | — | — | WO | claimed |
| CN-1961666-B | Anti-microbial composition | BYOTROL LLC | 2011-06-22 | — | — | CN | claimed |
| EP-2313026-A1 | ACTIVE DELIVERY SYSTEM FORMULATIONS | Castle Beach, L.L.C. (US) | 2011-04-27 | — | — | EP | claimed |
| EP-0969846-B2 | COMPOSITIONS AND METHODS FOR REDUCING OCULAR HYPERTENSION | NOVARTIS AG (CH) | 2010-08-25 | — | — | EP | claimed |
| US-7674473-B2 | Anti-microbial composition | BYOTROL PLC (GB) | 2010-03-09 | — | — | US | claimed |
| US-20100040565-A1 | ACTIVE DELIVERY SYSTEMS FORMULATIONS | Castle Beach, LLC (US) | 2010-02-18 | — | — | US | claimed |
| WO-2010019680-A1 | ACTIVE DELIVERY SYSTEM FORMULATIONS | HOMOLA ANDREW M (US) | 2010-02-18 | — | — | WO | claimed |
| EP-1549731-B1 | CLEANING AND DISINFECTING COMPOSITION | RECKITT BENCKISER INC (US) | 2008-12-17 | — | — | EP | claimed |
| EP-1347684-B1 | ANTI-MICROBIAL COMPOSITION | BYOTROL PLC (GB) | 2008-05-28 | — | — | EP | claimed |
| EP-0969846-B1 | COMPOSITIONS AND METHODS FOR REDUCING OCULAR HYPERTENSION | NOVARTIS AG (CH) | 2004-01-07 | — | — | EP | claimed |
| EP-1347684-A1 | ANTI-MICROBIAL COMPOSITION | Byotrol LLC (GB) | 2003-10-01 | — | — | EP | claimed |
| US-20030031687-A1 | First compound having a high surface tension of 20-35 mN/m, second compound having a low surface tension of 8-14 mN/ m, a first anti-microbial agent and a polar solvent | BYOTROL LLC | 2003-02-13 | — | — | US | claimed |
| US-20020137631-A1 | Anti-microbial composition | FALDER STEPHEN BRIAN (GB) | 2002-09-26 | — | — | US | claimed |
| WO-2002062142-A1 | ANTI-MICROBIAL COMPOSITION | BYOTROL LLC (GB) | 2002-08-15 | — | — | WO | claimed |
| US-20020002185-A1 | Compositions and methods for reducing ocular hypertension | R-TECH UENO, LTD. (JP) | 2002-01-03 | — | — | US | claimed |
| CN-1249687-A | Compositions and methods for reducing ocular hypertension | NOVARTIS AG (CH) | 2000-04-05 | — | — | CN | claimed |
| EP-0969846-A1 | COMPOSITIONS AND METHODS FOR REDUCING OCULAR HYPERTENSION | Novartis AG (CH) | 2000-01-12 | — | — | EP | claimed |
| WO-1998041208-A1 | COMPOSITIONS AND METHODS FOR REDUCING OCULAR HYPERTENSION | NOVARTIS AG (CH) | 1998-09-24 | — | — | WO | claimed |
| US-5665333-A | Methods, compositions, and dental delivery systems for the protection of the surfaces of teeth | PROVSEAL LLC | 1997-09-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100040565-A1 | ACTIVE DELIVERY SYSTEMS FORMULATIONS | LIPA, MMP7, CTSA | ALOX5 716/4885PTGS2 342/4885TYR 3186/4885 |
| US-20020002185-A1 | Compositions and methods for reducing ocular hypertension | PTGIS, PTGIR, PDE3A | ALOX5 17/4885PTGS2 19/4885TYR 3370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.